newsfilter
← Latest News
GlobeNewswire·

First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company

Phase 3-ready latiglutenase, a targeted oral biotherapeutic for celiac disease, will expand First Wave BioPharma's late-stage gastrointestinal (GI) disease clinical pipeline A concurrent institutional investment and a